James Crowe

Jens Meiler, Distinguished Research Professor of Chemistry, was named the principal investigator for the project, in cooperation with 14 investigators across eight institutions. The team will work together to use advanced technology, including computational modeling, AI-driven predictions and structural biology, to develop a groundbreaking vaccine against all alphaviruses that offers long-lasting protection. Read More

Jad Abumrad, Distinguished Research Professor of Communication of Science and Technology and creator of Vanderbilt’s Quantum Potential series, talks to Vanderbilt Magazine about this groundbreaking project, described as a collection of wild but precise portraits of the scholars, scientists and students at Vanderbilt who are finding new ways to understand the world—and change it. Read More

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers. Read More

Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read More

WATCH: Today’s fight against infectious diseases is being waged in the computer lab as much as the wet lab. Using artificial intelligence and machine learning, Vanderbilt researchers and students like School of Engineering undergraduate Karen Pu are expanding the power of computer modeling to identify mutating viruses—and potentially improve vaccines. Read More

Quantum Potential is a collection of wild but precise portraits of the scholars, scientists and students at Vanderbilt who are finding new ways to understand the world—and change it. A premiere event will take place Oct. 11 at 6 p.m., including a screening of two short films, behind-the-scenes discussions and an immersive performance. The event is open the general public; registration is required. Read More

Seed and Series A funding to three startups—HeroWear, IDBiologics and Virtuoso—rooted in research conducted at Vanderbilt University and Vanderbilt University Medical Center underscore a university-wide commitment to enhanced support for Vanderbilt’s most innovative faculty, students and alumni. Read More

Two Vanderbilt faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine. TIME’s Best Inventions of 2022 Cover “These winning innovations exemplify the transformative potential of university research when it aims to solve society’s most urgent problems, and when universities partner with the broader innovation ecosystem to bring... Read More

Two Vanderbilt faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine. TIME’s Best Inventions of 2022 Cover “These winning innovations exemplify the transformative potential of university research when it aims to solve society’s most urgent problems, and when universities partner with the broader innovation ecosystem to bring... Read More

Two Vanderbilt University faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine.  Read More

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization. Read More

Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM). Read More

U.S. Cyber Command Director Gen. Paul Nakasone, former President of Estonia Kersti Kaljulaid and a range of military and intelligence leaders, scholars, prominent journalists and private sector experts in cybersecurity, energy and finance convened at the Vanderbilt Summit on Modern Conflict and Emerging Threats May 4–5. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

Chancellor Daniel Diermeier will share his priorities and aspirations for the new academic year and present some of the university’s highest honors at the Fall Faculty Assembly on Thursday, Aug. 26. Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.  Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca. Read More